FDA Grants Priority Review to NDA for TransCon CNP
FDA Grants Priority Review to Ascendis Pharma’s NDA for TransCon® CNP in Achondroplasia Treatment Ascendis Pharma A/S a biopharmaceutical company focused on developing innovative therapies for patients with serious rare…
Protagonist & Takeda to Present Full 32-Week Phase 3 VERIFY Results on Rusfertide at ASCO
Protagonist Therapeutics and Takeda Reveal Comprehensive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera at ASCO 2025 Protagonist Therapeutics,and Takeda Pharmaceutical Company Limited have announced detailed findings from…
Sanofi to Acquire Blueprint, Boosting Rare Immunology Portfolio
Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal, Expanding Rare Immunological Disease Portfolio and Deepening Immunology Pipeline In a landmark move to expand its presence in rare immunological diseases…
Kisqali Cuts Recurrence Risk in Young Breast Cancer Patients: NATALEE Subgroup
Novartis Highlights Kisqali’s Promise in Reducing Recurrence Risk for Younger Patients with Early Breast Cancer at ASCO 2025 At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Novartis…
Camizestrant Cuts Risk of Progression or Death by 56% in ESR1-Mutant HR+ Breast Cancer
AstraZeneca’s Camizestrant Shows Landmark Efficacy in Advanced HR-Positive Breast Cancer with ESR1 Mutations in Phase III SERENA-6 Trial In a pivotal breakthrough for hormone receptor (HR)-positive, HER2-negative advanced breast cancer,…
Imfinzi Regimen Cuts Early Gastric Cancer Risk by 29% in Phase III Trial
AstraZeneca’s Imfinzi-Based Regimen Shows Significant Benefit in Early Gastric and GEJ Cancers in Phase III MATTERHORN Trial AstraZeneca has reported highly promising results from its Phase III MATTERHORN trial, showcasing…
Roche’s Fenebrutinib Sustains Disease Control in Relapsing MS for Two Years
Roche Reports Promising Two-Year Results for Fenebrutinib in Relapsing Multiple Sclerosis, Maintaining Disease Control and Halting Disability Progression Roche has released encouraging new long-term data from its investigational Bruton’s tyrosine…
Merck’s Zilovertamab Vedotin Shows Promising Results in Phase 2 DLBCL Trial
Merck’s Zilovertamab Vedotin in Combination With R-GemOx Shows Promising Efficacy in Relapsed/Refractory DLBCL Patients: Phase 2 Results from waveLINE-003 Trial Presented at ASCO 2025 Merck, known as MSD outside the…
Merck’s KRAS G12C Inhibitor MK-1084 Shows Antitumor Activity in Early Trial
Merck Reports Encouraging Early Data for Investigational KRAS G12C Inhibitor MK-1084 in Phase 1 Trial for Advanced Colorectal and Lung Cancers Merck known as MSD outside the United States and…
AbbVie and Chicago Cubs Join Forces in the Fight Against Cancer
AbbVie and the Chicago Cubs Launch Multi-Year “Striking Out Cancer” Campaign to Support Cancer Awareness and Research In a bold and heartfelt effort to turn America’s favorite pastime into a…
Teva Launches Acceleration Phase of Growth Strategy at 2025 Innovation Day
Teva Embarks on Acceleration Phase of “Pivot to Growth” Strategy at 2025 Innovation & Strategy Day, Signaling Renewed Focus on Biopharmaceutical Leadership and Long-Term Shareholder Value Teva Pharmaceutical Industries Ltd.one…
China Accepts NDA for Naldemedine to Treat Opioid-Induced Constipation
China Accepts New Drug Application for Shionogi’s Naldemedine to Treat Opioid-Induced Constipation Shionogi & Co., Ltd., a leading Japanese pharmaceutical company headquartered in Osaka, has announced a key regulatory milestone…